TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01772420
Drug: Eltrombopag Olamine
Normalized name: Eltrombopag Olamine
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01772420
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03954015
Drug: Lumason
Normalized name: Lumason
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
Study: NCT02894151
Drug: Depot medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02116543
Drug: TD-6450
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01930045
Drug: Raltegravir (ISENTRESS™)
Normalized name: raltegravir Oral Tablet [Isentress]
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
Study: NCT01930045
Drug: MAALOX (MAL)
Normalized name: Maalox
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1
Study: NCT03130439
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
Study: NCT02662855
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral administration of Favipiravir tablets
Study: NCT02891278
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM.
Study: NCT02891278
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours).
Study: NCT00507689
Drug: Hepatitis B Immunoglobulin (HBIg)
Normalized name: hepatitis B immunoglobulin
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
Study: NCT01976624
Drug: bimatoprost/timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
Study: NCT05345119
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
Study: NCT05345119
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
Study: NCT02749578
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01518634
Drug: Imipramine treatment
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
Study: NCT02587130
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine administered in bolus by subcutaneous injection
Study: NCT00779545
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
Study: NCT00779545
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
Study: NCT00779545
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Study: NCT00779545
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
Study: NCT00779545
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Study: NCT03129867
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 60mg or 90 mg as routine use of each Center
Study: NCT03861767
Drug: Metformin ER
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet
Study: NCT01436838
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
Study: NCT03422055
Drug: 99mTc-Fucoidan SPECT
Normalized name: Fucidin
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
Study: NCT02939365
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
Study: NCT01188499
Drug: Birinapant
Normalized name: Birinapant
DrugBank: Birinapant (DB11782)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04101370
Drug: Bosentan 125 mg
Normalized name: bosentan 125 MG
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
Study: NCT04101370
Drug: Tracleer 125Mg Tablet
Normalized name: Tracleer 125mg Tablet
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
Study: NCT01582061
Drug: Pasireotide sub-cutaneous
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
Study: NCT04440267
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: L-Asparaginase
Normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT03050151
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
Study: NCT00130858
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00130858
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00702468
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
Study: NCT00366171
Drug: Bifeprunox
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01611467
Drug: CC-223
Normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
Study: NCT01611467
Drug: CC-223
Normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg oral CC-223 tablet under fasting or fed conditions
Study: NCT00004249
Drug: polysialic acid
Normalized name: polygalic acid
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03309566
Drug: Efavirenz, tenofovir disoproxil fumarate and emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
Study: NCT00845832
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
Study: NCT01391130
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT00309088
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00783354
Drug: desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months.
Study: NCT00783354
Drug: desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months.
Study: NCT02602743
Drug: Remifentanyl
Normalized name: Remifentanyl
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
Study: NCT02602743
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
Study: NCT02602743
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg ketamine will be administered for induction in 1 minute.
Study: NCT01568918
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
Study: NCT02129582
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02129582
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02129582
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT01422616
Drug: Low-dose rtPA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
Study: NCT00429559
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression
Study: NCT01039142
Drug: Acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
Study: NCT04408937
Drug: triopifexor
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor as a dry blend in hard gelatin capsules for oral administration
Study: NCT00002972
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00640484
Drug: carmoterol (CHF 4226)
Normalized name: CHF-6333
DrugBank: Carmoterol (DB15784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)
Study: NCT03226899
Drug: Lesinurad
Normalized name: Lesinurad
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg oral tablet
Study: NCT03226899
Drug: colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
Study: NCT04257136
Drug: VBI-S
Normalized name: S-2
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
Study: NCT01291381
Drug: Dermatophagoides pteronyssinus
Normalized name: Dermatophagoides pteronyssinus
DrugBank: Dermatophagoides pteronyssinus (DB10401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
Study: NCT00640484
Drug: carmoterol (CHF 4226)
Normalized name: CHF-6333
DrugBank: Carmoterol (DB15784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)
Study: NCT00640484
Drug: salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)
Study: NCT00118183
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00118183
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02052219
Drug: Blisibimod
Normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blisibimod administered subcutaneously
Study: NCT03250052
Drug: (fimasartan or linagliptin) x 7days
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A: fimasartan, Part B: linagliptin
Study: NCT03250052
Drug: (fimasartan and linagliptin) x 7days
Normalized name: metformin and linagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part A \& Part B: Co-administration of fimasartan and linagliptin
Study: NCT01351272
Drug: Methylphenidate, non-retard
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
Study: NCT00407082
Drug: fluocinolone acetonide intravitreal implant
Normalized name: Fluocinolone Acetonide Intravitreal Implant
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide ocular implant 0.59mg
Study: NCT00407082
Drug: Fluocinolone acetonide 2.1mg
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide ocular implant 2.1mg
Study: NCT00232622
Drug: Streptokinase
Normalized name: Streptokinase
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated infusion of streptokinase
Study: NCT00232622
Drug: Streptokinase
Normalized name: Streptokinase
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose streptokinase
Study: NCT02210806
Drug: A006 DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose 110 mcg, 1 inhalation
Study: NCT02210806
Drug: A006 DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose 220 mcg, 1 inhalation
Study: NCT02273986
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02273986
Drug: K-877
Normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02084485
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 MG Single dose
Study: NCT00657046
Drug: Droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules containing 200 mg droxidopa
Study: NCT03470675
Drug: Epidural morphine 3 mg + IV ketamine 0.3 mg/kg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
Study: NCT00430469
Drug: human lactoferrin (hLF1-11)
Normalized name: lactoferrin (synthetic human)
DrugBank: Human Lactoferrin Peptide hLF1-11 (DB16245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous 0.5mg in NaCl-solution
Study: NCT01359592
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01359592
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02001623
Drug: Tisotumab Vedotin (HuMax-TF-ADC)
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02091336
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients treatment
Study: NCT02091336
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients treatment
Study: NCT00020449
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes